Bavarian Nordic is working with EMA on monkeypox vaccine label expansion

Bavarian Nordic’s smallpox vaccine Imvanex has previously been used off-label to protect close contacts from monkeypox in several countries. The Danish vaccine firm is now working with the EMA to expand the label in an ”accelerated process.”

Photo: Bavarian Nordic / PR

On Tuesday the EMA announced that it had started assessing whether Bavarian Nordic’s smallpox vaccine could be used to combat the ongoing monkeypox outbreak in Europe.

The statement from the EMA mentioned that the authority was waiting for a formal label expansion application for the vaccine, which is called Imvanex in the region.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs